NCT03643510 2026-03-16
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
Clinical Trials
10 trialsNCT03531645 2026-03-05
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01560416 2026-03-03
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02860000 2026-02-27
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
Mayo Clinic
Phase 2 Completed
NCT05467891 2026-02-27
RaPhLRR
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06179303 2026-02-27
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT02778685 2026-02-24
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03179904 2026-02-24
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT07426822 2026-02-24
SAFE-CAP
Yale University
Phase 2 Not yet recruiting
NCT06494150 2026-02-23
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
University of Oklahoma
Phase 2 Recruiting